- Home
- LPCN
LPCN
Lipocine Inc.
as 12-20-2024 4:00pm EST
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | SALT LAKE CITY |
| Market Cap: | 36.8M | IPO Year: | N/A |
| Target Price: | $10.00 | AVG Volume (30 days): | 33.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.44 - $11.79 | Next Earning Date: | 11-07-2024 |
| Revenue: | $7,922,926 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | -61.96% |
Latest Lipocine Inc. News
LPCN Breaking Stock News: Dive into LPCN Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
Sector Update: Health Care
MT Newswires
5 days ago
Lipocine Says LPCN 1148 Gets FDA Fast Track Label
PR Newswire
6 days ago
FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis
PR Newswire
a month ago
Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session
PR Newswire
2 months ago
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024
Associated Press Finance
2 months ago
Lipocine: Q3 Earnings Snapshot
PR Newswire
2 months ago
Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea
PR Newswire
2 months ago
Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results
Compare LPCN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LPCN Lipocine Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.